OTHER INFORMATION
of 'Bosutinib'
|
| Therapeutic : |
Anti-Cancer / Oncology |
| Therapeutic : |
Anti-Cancer / Oncology |
| IUPAC Name : | 4-(2,4-dichloro-5-methoxyanilino)-6-methoxy-7-[3-(4-methylpiperazin-1-yl)propoxy]quinoline-3-carbonitrile |
| Chemical name of this compound, computed from its structure based on the International Union of Pure and Applied Chemistry (IUPAC) nomenclature standards. |
| Applicationnotes : | "A novel Src kinase inhibitor, suppresses migration and invasion of human breast cancer cells. " |
| Synonym : | Not available |
| References : | "Bjorge, J,, et al,: J, Biol, Chem,, 275, 41439" |
| Smileys : | ClC1=CC(Cl)=C(OC)C=C1NC(C2=C3C=C(OCCCN4CCN(C)CC4)C(OC)=C2)=C(C=N3)C#N |
| Use Classification : | Human drugs -> Bosulif -> EMA Drug Category |
| This section contains use classification/category information for this compound from various sources. |
| EC Number : | 700-455-1 |
| The European Community (EC) number is a seven-digit identifier assigned by the European Chemicals Agency (ECHA) to substances for regulatory purposes within the European Union. EC numbers are sometimes referred to as EINECS, ELINCS, or NLP numbers |
| UNII : | 5018V4AEZ0 |
| UNique Ingredient Identifier (UNII) code for this chemical. It is a non-proprietary registry number assigned by the U.S. Food and Drug Administration (FDA). |
| NCI Thesaurus Code : | C60809 |
| Stable, unique code for biomedical concept |
| RXCUI : | 1307619 |
| Stable, unique code for biomedical concept |
| MeSH Entry Terms : | bosutinib |
| Medical Subject Heading (MeSH) names or identifiers matching this PubChem Compound record. The matching between the MeSH and compound records is performed by name matching (i.e., identical common names) |
| Other Synonyms : | Bosutinib |
| Removed Synonyms : | bosutinib hydrate |
| Metabolite Pathways : | Bosutinib Inhibition of BCR-ABL |
| Metabolic pathways related to this chemical. A metabolic pathway is a series of chemical reactions in a cell that build and breakdown molecules for cellular processes. |
| Toxicity Summary : | Most common adverse reactions (incidence greater than 20%) are diarrhea, nausea, thrombocytopenia, vomiting, abdominal pain, rash, anemia, pyrexia, and fatigue. Because bosutinib is not an inhibitor of c-KIT or PDGF receptor, it has less hematologic toxicities. |
| Summary of the toxicity of this compound, provided by the Hazardous Substances Data Bank (HSDB). |
| Hepatotoxicity : | In large clinical trials of bosutinib, elevations in serum aminotransferase levels were common, occurring in up to 58% of bosutinib treated patients. Values greater than 5 times the upper limit of normal (ULN) occurred in 4% to 19% of bosutinib recipients (and 3% of imatinib treated subjects). These abnormalities were usually asymptomatic, but led to discontinuation of therapy in up to 2% of treated patients. In addition, there have been isolated reports of clinically apparent liver injury attributed to bosutinib therapy, although the frequency of this outcome and the clinical features of the injury have not been well defined. The time to onset has generally been within 3 months and the pattern of serum enzyme elevations was usually hepatocellular. |
| This section provides a short description about the hepatotoxicity associated with this compound, the rate of serum enzyme elevations during use, and the frequency and character of the clinically apparent liver injury associated with the compound. |
| Protein Binding : | 94% bound to human plasma proteins in vitro. 96% bound to human plasma proteins in healthy subjects ex vivo. Extent of protein binding is not concentration-dependent. |
| In this section, "protein binding" refers to the degree to which medications attach to plasma proteins (i.e., proteins within the blood, such as human serum albumin, lipoprotein, glycoprotein and globulins) |
| Exact Mass : | 529.1647452 |
| The exact mass of an isotopic species is obtained by summing the masses of the individual isotopes of the molecule. |
| InChI : | InChI=1S/C26H29Cl2N5O3/c1-32-6-8-33(9-7-32)5-4-10-36-25-13-21-18(11-24(25)35-3)26(17(15-29)16-30-21)31-22-14-23(34-2)20(28)12-19(22)27/h11-14,16H,4-10H2,1-3H3,(H,30,31) |
| The International Chemical Identifier (InChI) is a computed, non-proprietary identifier for a chemical structure. The InChI is an International Union of Pure and Applied Chemistry (IUPAC) standard. |
| InchIKey : | UBPYILGKFZZVDX-UHFFFAOYSA-N |
| An InChIKey is a 27-character hash code derived from an InChI. The International Chemical Identifier (InChI) is a computed, non-proprietary identifier for a chemical structure. |
| Canonical SMILES : | CN1CCN(CC1)CCCOC2=C(C=C3C(=C2)N=CC(=C3NC4=CC(=C(C=C4Cl)Cl)OC)C#N)OC |
| The Simplified Molecular-Input Line-Entry System (SMILES) is a widely-used line notation for chemical structures. |
| Isomeric SMILES : | CN1CCN(CC1)CCCOC2=C(C=C3C(=C2)N=CC(=C3NC4=CC(=C(C=C4Cl)Cl)OC)C#N)OC |
| The Simplified Molecular-Input Line-Entry System (SMILES) is a widely-used line notation for chemical structures. |
| Product Description : | Bosutinib is an aminoquinoline that is 4-[(2,4-dichloro-5-methoxyphenyl)amino]-7-[3-(4-methylpiperazin-1-yl)propoxy]quinoline bearing additional cyano and methoxy substituents at positions 3 and 6 respectively. It has a role as an antineoplastic agent and a tyrosine kinase inhibitor. It is a nitrile, a N-methylpiperazine, an aromatic ether, a tertiary amino compound, an aminoquinoline and a dichlorobenzene. |
| Custom Duty : |
Applicable |
| Port of Loading : |
Canada |
| Expected Dispatch : |
15-Aug-2022 |
| Taxes : |
Not Applicable |
| Refund Policy : |
30-days money back |
| Custom Duty : |
Applicable |
| Port of Loading : |
Canada |
| Expected Dispatch : |
15-Aug-2022 |
| Taxes : |
Not Applicable |
| Refund Policy : |
30-days money back |
